Survival Benefit of Pancreatic Metastasectomy for Clear Cell Renal Cell Carcinoma

0
0
0

Survival Benefit of Pancreatic Metastasectomy for Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC)—the most common type of kidney cancer—has a unique tendency to spread to the pancreas. While Western studies have shown promising results for pancreatic metastasectomy (surgical removal of pancreatic metastases) in these patients, data from East Asian populations remains scarce. To fill this gap, researchers from the Department of Pancreatic Surgery and Department of Radiology at Zhongshan Hospital, Fudan University, Shanghai, China—led by Yuan Fang, Min Tang, Wen-Tao Zhou, and Wen-Hui Lou—analyzed their 12-year experience with this rare condition. Their findings, published in the Chinese Medical Journal, offer valuable insights into survival outcomes and surgical safety for East Asian patients.

The Study: Who Was Included?

The team used a prospectively maintained surgical database to identify 10 patients with pancreatic metastases from ccRCC treated between July 2007 and April 2019. All patients had previously undergone surgery for their primary kidney cancer (6 on the right kidney, 4 on the left). Most (9) had early-stage ccRCC (TNM stage II), with one patient at stage III. Two patients had recurrent kidney cancer in the opposite kidney before their pancreatic metastasis, and one had a prior lung metastasis treated with surgery.

Key context: Pancreatic metastases from ccRCC are extremely rare—they made up just 0.5% of all pancreatic malignancies at the hospital during the study period (10 out of 2,000 cases).

What Did They Find?

1. Diagnosis and Imaging

Most patients (8 out of 10) had no symptoms—their pancreatic metastases were found during routine abdominal imaging surveillance. Only two reported upper abdominal pain. All computed tomography (CT) scans revealed a telltale sign of ccRCC metastases: hyper-vascular lesions (blood-rich) that brightened strongly and uniformly in the early (arterial) phase of contrast imaging—more so than normal pancreatic tissue. These lesions often “disappeared” in later imaging phases, making early-phase CT critical for diagnosis.

2. Surgical Details

The median time from kidney cancer surgery to pancreatic metastasis was 73.4 months (nearly 6 years)—though this ranged widely (4.4 to 182.7 months, or 15 years). Most metastases were solitary (9 out of 10) and located in the pancreatic head (4 cases) or body/tail (5 cases); one patient had multifocal disease (head + body/tail). The median size of the pancreatic tumor was 2.4 cm (0.9 to 4.9 cm).

All patients underwent R0 resection—complete removal of the metastasis with no remaining cancer cells. Surgeries included:

  • Distal pancreatectomy (removing the body/tail): 5 cases
  • Pancreaticoduodenectomy (removing the head, common bile duct, duodenum): 4 cases
  • Total pancreatectomy (removing the entire pancreas): 1 case

Importantly, there were no deaths around the time of surgery. Only two patients experienced complications: one had a mild pancreatic fluid leak (grade B), and another had a more severe leak (grade C). Overall, the surgical safety profile was strong—especially for a high-volume pancreatic center.

3. Survival Outcomes

The median follow-up period was 59.6 months (nearly 5 years). Six patients remained alive at the last follow-up, while four had died (all from cancer-related causes). The median overall survival after pancreatic metastasectomy was 77 months—meaning half the patients lived longer than 6.4 years. Survival rates were striking:

  • 1 year: 100% (all alive)
  • 3 years: 100% (all alive)
  • 5 years: 60% (6 out of 10 alive)

Post-surgery treatments varied: Two patients received targeted therapy (sorafenib or pazopanib), one had chemotherapy (5-fluorouracil + gemcitabine), and one had liver metastasis treated with transarterial chemoembolization (TACE). Most (6) had no additional treatment.

What Does This Mean for Patients and Doctors?

The study’s biggest takeaway is that pancreatic metastasectomy can offer long-term survival for select ccRCC patients—with low risk of surgery-related death and manageable complications. This aligns with Western research but adds critical data from East Asian patients, who were underrepresented in prior studies.

However, the findings come with caveats. A 2015 Italian multicenter study of 103 patients found no significant survival difference between pancreatic surgery and tyrosine kinase inhibitors (TKIs)—a type of targeted therapy. This means more large, multi-center studies are needed to confirm whether surgery is better than non-surgical options.

Another debate: Should surgeons perform “typical” resections (like removing the entire pancreatic head) or “atypical” ones (only digging out the metastasis) to preserve pancreatic function? Some studies suggest that smaller resections protect the pancreas’s ability to make digestive enzymes and insulin—especially important given ccRCC’s slow-growing nature.

Limitations and Next Steps

The study’s small size (10 patients) and single-center design mean it can’t answer all questions—like which patients are most likely to benefit from surgery. Other limitations include:

  • No standardized post-surgery treatment plans for either the primary kidney cancer or pancreatic metastasis.
  • Difficulty running a prospective trial for such a rare condition.

Still, the results are valuable. They show that for patients with isolated pancreatic metastases from ccRCC—especially those caught early via surveillance—surgery can be a safe, effective option.

Conclusion

For East Asian patients with pancreatic metastases from clear cell renal cell carcinoma, pancreatic metastasectomy offers a meaningful chance at long-term survival. The procedure is safe in high-volume centers, with low mortality and manageable complications. However, every case is unique—doctors must carefully evaluate factors like tumor size, location, and patient health before recommending surgery.

As research expands, we’ll gain a clearer picture of who benefits most from this approach. For now, this study adds an important piece to the puzzle for patients and clinicians alike.

The original study was published in the Chinese Medical Journal in 2019. You can access it at doi.org/10.1097/CM9.0000000000000500.

The research was supported by the National Natural Science Foundation of China (grant No. 81702964). All patients provided informed consent, and the study was approved by the Zhongshan Hospital Ethical Committee.

Was this helpful?

0 / 0